1-3 of 3
Stephen S. Opat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

Clinical Trials & Observations
Maciej Tatarczuch, Mark Waltham, Jake Shortt, Galina Polekhina, Eliza A. Hawkes, Shir-Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica Li, Vanitha Ramakrishnan, Karin Dunne, Stephen S. Opat, Gareth P. Gregory
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3531–3539.
https://doi.org/10.1182/bloodadvances.2022009412
Published: 2023
Includes: Supplemental data
Journal Articles

Salvage radiotherapy is associated with durable response for a subset of patients with limited-stage refractory DLBCL

Clinical Trials & Observations
Jemima H. Miller, Michael Gilbertson, Michael P. MacManus, Andrew Wirth, Stephen S. Opat, Gareth P. Gregory
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5112–5115.
https://doi.org/10.1182/bloodadvances.2021005061
Published: 2021
Includes: Supplemental data
Journal Articles

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

Clinical Trials & Observations
Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S. Kaplan, James D. McFadyen, Huyen Tran, Tse-Chieh Teh, Shaun Fleming, John V. Catalano, Sanjeev D. Chunilal, Anna Johnston, Stephen S. Opat, Jake Shortt
Journal: Blood Advances
Blood Adv (2016) 1 (1): 31–35.
https://doi.org/10.1182/bloodadvances.2016001412
Published: 2016